Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A call for physiopathological ethics.

× No keyword cloud information.

13 in total

1. Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials.

Authors: Jonathan Kimmelman
Journal: Mol Ther Date: 2007-11 Impact factor: 11.454

2. Human gene therapy, consent, and the realities of clinical research: is it time for a research subject advocate?

Authors: Tomas Jose Silber
Journal: Hum Gene Ther Date: 2008-01 Impact factor: 5.695

3. If it's broken, shouldn't it be fixed? Informed consent and initial clinical trials of gene therapy.

Authors: Arthur L Caplan
Journal: Hum Gene Ther Date: 2008-01 Impact factor: 5.695

4. Informed consent in human gene transfer clinical trials.

Authors: Jeffrey Kahn
Journal: Hum Gene Ther Date: 2008-01 Impact factor: 5.695

5. Progress reported in two studies of clinical gene transfer into the retina.

Authors: David A Williams
Journal: Mol Ther Date: 2008-07 Impact factor: 11.454

6. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Authors: William J Marks; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Larson; Roy Ae Bakay; Robin Taylor; Deborah A Cahn-Weiner; A Jon Stoessl; C Warren Olanow; Raymond T Bartus
Journal: Lancet Neurol Date: 2008-04-02 Impact factor: 44.182

7. Protections for participants in gene therapy trials: a patient's perspective.

Authors: Suzanne R Pattee
Journal: Hum Gene Ther Date: 2008-01 Impact factor: 5.695

8. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Authors: Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During
Journal: Lancet Date: 2007-06-23 Impact factor: 79.321

9. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors: William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal: Hum Gene Ther Date: 2008-10 Impact factor: 5.695

10. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Authors: Andrew Feigin; Michael G Kaplitt; Chengke Tang; Tanya Lin; Paul Mattis; Vijay Dhawan; Matthew J During; David Eidelberg
Journal: Proc Natl Acad Sci U S A Date: 2007-11-27 Impact factor: 11.205

5 in total

1. Risk in clinical research: size matters!

Authors: Pedro R Lowenstein
Journal: Mol Ther Date: 2009-11 Impact factor: 11.454

Review 2. Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?

Authors: Claire T Deakin; Ian E Alexander; Ian Kerridge
Journal: Mol Ther Date: 2009-09-22 Impact factor: 11.454

Review 3. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Authors: Pedro R Lowenstein; Maria G Castro
Journal: Curr Gene Ther Date: 2009-10 Impact factor: 4.391

4. Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials.

Authors: Pedro R Lowenstein; Elijah D Lowenstein; Maria G Castro
Journal: Curr Opin Mol Ther Date: 2009-10

5. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

Authors: Jonathan Kimmelman; Alex John London
Journal: PLoS Med Date: 2011-03-08 Impact factor: 11.069

5 in total